SCARNA18B

Across TCGA pan-cancer cohorts, SCARNA18B RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated SCARNA18B data layer.

The strongest signal is observed in mesothelioma (MESO), where higher SCARNA18B RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SCARNA18B expression acts as an unfavorable survival marker, although some lineages such as STAD and COAD show a favorable association.

MESO, UVM, and KIRC are the cancer types where SCARNA18B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	III,IV	0.077	0.580	<.001	72	view →
UVM	OS	Tertile	All	0.218	0.696	.014	54	view →
KIRC	DFS	Tertile	IV	0.092	0.631	.013	36	view →
STAD	DFS	Median	II,III,IV	0.712	0.344	.001	33	view →
COAD	DFS	Tertile	All	1.000	0.522	.022	27	view →
CESC	OS	Tertile	All	0.913	0.771	.017	24	view →
UCEC	DFS	Tertile	All	0.800	0.906	.003	24	view →
THCA	OS	Tertile	III,IV	0.611	0.977	.013	21	view →
ACC	DFS	Tertile	II,III,IV	0.068	0.631	.011	18	view →
LUSC	DFS	Tertile	II,III,IV	0.854	0.695	.023	15	view →
ESCA	DFS	Quartile	All	0.396	0.872	.027	9	view →
LIHC	DFS	Tertile	All	0.210	0.532	.047	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

SCARNA18B–MESO (OS)

Open the MESO breakdown →